Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Kiora Pharmaceuticals, Inc.
eyegatepharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Kiora Pharmaceuticals' Chief Development Officer Eric J. Daniels is resigning effective April 17, 2026, to pursue another opportunity. This leadership transition could impact the company's drug development strategy and pipeline execution.
Key Takeaways
Eric J. Daniels, M.D., MBA will depart as Chief Development Officer on April 17, 2026
Resignation is voluntary and not due to any disagreement with company operations or policies
2 more takeaways
Related Filings (2)
2 more filings from Kiora Pharmaceuticals, Inc. in the last 90 days